Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3724 publications
Hepatotoxicity of ALK/ROS1 tyrosine kinase inhibitors in non-small cell lung cancer patients: A pharmacovigilance study based on signal mining and analysis of the FDA adverse event reporting system database.
Journal: Science progress
Published: October 15, 2025
Prevailing challenges in companion diagnostic test development for lung cancer.
Journal: Expert review of anticancer therapy
Published: October 11, 2025
Real-World Outcomes in Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer in Argentina: A Multicenter Retrospective Study (GAOT-ALK001).
Journal: JCO global oncology
Published: October 03, 2025
Conjunctival TFG::ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor Treated With Crizotinib.
Journal: Ophthalmic plastic and reconstructive surgery
Published: September 16, 2025
Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Journal: Journal of managed care & specialty pharmacy
Published: August 30, 2025
Branches of Deception: A Tree-in-Bud Pattern Revealing Advanced Non-small Cell Lung Cancer (NSCLC).
Journal: Cureus
Published: August 23, 2025
\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 19, 2025
Real-World Outcomes of Brigatinib Compared to Alectinib as a Second-Line Therapy After Crizotinib in Advanced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients.
Journal: Thoracic cancer
Published: August 14, 2025
Taletrectinib (Ibtrozi) - another kinase inhibitor for non-small cell lung cancer (NSCLC).
Journal: The Medical letter on drugs and therapeutics
Published: July 29, 2025
Sex differences in cardiotoxicity of anaplastic lymphoma kinase inhibitors: An analysis of the FDA Adverse Event Reporting System.
Journal: Oncology
Published: July 24, 2025
Last Updated: 10/31/2025